A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors by Ivan Diaz-Padilla et al.
PHASE I STUDIES
A phase Ib combination study of RO4929097,
a gamma-secretase inhibitor, and temsirolimus in patients
with advanced solid tumors
Ivan Diaz-Padilla & Hal Hirte & Amit M. Oza & Blaise A. Clarke & Brenda Cohen &
Michael Reedjik & Tong Zhang & Suzanne Kamel-Reid & S. Percy Ivy &
Sebastien J. Hotte & Albiruni A. R. Razak & Eric X. Chen & Irene Brana &
Monika Wizemann & Lisa Wang & Lillian L. Siu & Philippe L. Bedard
Received: 10 June 2013 /Accepted: 4 July 2013 /Published online: 17 July 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Summary Background To determine the recommended
phase II dose (RP2D) and assess the safety, pharmacokinet-
ics (PKs) and pharmacodynamics of RO4929097in combi-
nation with temsirolimus. Methods Escalating doses of
RO4929097 and temsirolimus were administered at three
dose levels. Patients received once daily oral RO4929097
on a 3 days on/4 days off schedule every week, and weekly
intravenous temsirolimus. Blood samples were collected for
PK analysis. Archival tissue specimens were collected for
Notch pathway biomarker analysis and genotyping of fre-
quent oncogenic mutations. Results Seventeen patients with
refractory advanced solid tumors were enrolled in three dose
levels (DLs): DL1 (RO4929097 10 mg; Temsirolimus
25 mg), DL2 (RO4929097 20 mg; Temsirolimus 25 mg),
and DL3 (RO4929097 20 mg; Temsirolimus 37.5 mg). The
most common toxicities related to the study drug combina-
tion included: fatigue (82 %; grade 3 6 %), mucositis, (71 %;
grade 3 6 %), neutropenia (59 %; grade 3 12 %), anemia
(59 %; grade 3 0 %), and hypertriglyceridemia (59 %; grade
3 0 %). Two dose-limiting toxicities, grade 3 rash and grade
3 mucositis, were observed in the same patient in the first
dose level prompting dose expansion. Eleven patients (73 %)
had stable disease as their best response. Co-administration
of RO4929097 was associated with increased clearance and
reduced exposure to temsirolimus, suggestive of drug-drug
interaction via CYP3A4 induction. No correlation between
the expression of Notch pathway biomarkers or genotype
and time to progression was noted. Conclusions RO4929097
can be safely combined with temsirolimus in patients with
advanced solid tumors. The RP2D was established at 20 mg
of RO4929097 combined with 37.5 mg of temsirolimus.
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Introduction
The Notch signaling pathway is highly conserved and plays
a critical role in regulating cell-to-cell communication during
embryogenesis, cellular proliferation, differentiation, and
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apoptosis [2]. Deregulation of Notch signaling has also been
involved in several malignancies [8, 10]. Increased Notch
signaling promotes tumor cell proliferation by maintaining
tumor cells in a stem-cell–like proliferative state. As a result,
Notch signaling inhibitors are being actively investigated for
the treatment of cancer. Mammalian-membrane-bound Notch
ligands consist of two structurally distinct families: Delta-like
ligands 1, 3 and 4, and Jagged ligands 1 and 2 that interact with
four transmembrane Notch receptors (Notch 1–4). Once
ligand-receptor binding occurs, the Notch receptor undergoes
a conformational change to expose previously protected sites
to proteolytic cleavage by metalloprotease and γ-secretase,
releasing the Notch intracellular domain (NICD) fragment
[11]. NICD translocates to the nucleus where it forms a
transcription-activating complex, thereby activating transcrip-
tion of target genes. Blocking Notch signaling via inhibition of
γ-secretase is an attractive therapeutic strategy. RO4929097 is
a potent and selective inhibitor of γ-secretase that produces a
less transformed, flattened, slower growing phenotype in a
variety of cancer cell lines [7]. In vivo studies established
antitumor activity in xenograft mouse models of colon, pan-
creatic, and non–small cell lung cancer with both continuous
and intermittent dosing, which persisted after cessation of
treatment [7].
A recently reported first-in-human phase I study evaluated
two different oral dosing schedules for RO4929097 given as a
single-agent [15]. RO4929097 was well tolerated at doses up
to 135 mgwhen administered for 7 consecutive days followed
by 14 days off treatment during a 21-day cycle. Administra-
tion of RO4929097was also evaluated on a three days-on/four
days-off schedule. No DLTs were observed in either dosing
regimen. Pharmacokinetic (PK) analysis showed that
RO4929097 exposure decreased after repeated dosing, due
to reversible CYP3A4 autoinduction at doses as low as 24 mg
in the 3-days on/4-days off schedule.
There is cross talk between the Notch and mammalian
target of rapamycin (mTOR) signaling pathways. The Notch
pathway regulates activation of both phosphatase and tensine
homologue (PTEN) and PI3K/AKT signaling components in
normal cells; however, the aberrant activation of Notch sig-
naling pathway induces the direct stimulation of PI3K/mTOR
pathway leading to tumor cell growth [8]. In vitro studies in
pancreatic cancer cell lines have shown a synergistic
antitumor effect mediated through enhancedAKTsuppression
when rapamycin and a γ-secretase inhibitor were administrat-
ed [16]. A recent in vitro study in T-cell acute lymphoblastic
leukemia model has shown that PI3K/mTOR inhibition leads
to upregulation of Notch-myc pathway. However, dual block-
ade of both PI3K/mTOR and Notch produces enhanced cell-
cycle arrest and cell death, providing a rationale for evaluating
temsirolimus in combination with RO4929097 [13].
The main objectives of this phase I clinical trial were i) to
determine the recommended phase II dose (RP2D) and
safety profile of temsirolimus in combination with
RO4929097; and ii) to evaluate the PK and pharmacody-
namic effects, and preliminary evidence of anticancer activ-
ity of the combination.
Patients and methods
Patient eligibility
Patients were required to have a histologically confirmed ad-
vanced, incurable solid malignancy that was refractory to
conventional therapy or for which no standard therapy existed,
age ≥18 years, life expectancy ≥12 weeks, an Eastern Coop-
erative Oncology Group (ECOG) Performance Status (PS) ≤1,
with adequate hematological, hepatic, and renal function. Prior
therapy with a γ-secretase inhibitor, or any inhibitor of the
PI3K/AKT/mTOR pathway was prohibited. Key exclusion
criteria included: a) concomitant use of medications that were
strong inducers/inhibitors or substrates of CYP3A4; b) patients
with malabsorption syndrome or other condition that would
interfere with intestinal absorption; c) uncontrolled hypocalce-
mia, hypomagnesemia, hyponatremia, hypophosphatemia or
hypokalemia despite adequate electrolyte supplementation; d)
a QTc interval ≥470 mSec as measured by Bazett’s formula; e)
pre-existing significant pulmonary infiltrates of unknown
origin.
The study was conducted at two institutions, the Princess
Margaret Cancer Centre and the Juravinski Cancer Centre.
The trial was approved by the Ontario Cancer Research
Ethics Board. The study was registered at clinicaltrials.gov
(NCT 01198184), sponsored by the Princess Margaret Hos-
pital Phase I Consortium, and supported by the National
Cancer Institute (NCI) Contract No. U01-CA132123.
Study design
This was an open-label, dose-escalation phase I trial.
RO4929097 was orally administered on an empty stomach
on a three days-on four days-off schedule, weekly; and
temsirolimus was given over 30 min intravenously (i.v.)
every week (Fig. 1). When both drugs were to be adminis-
tered together on a given day, RO4929097 was administered
first. Premedication with diphenhydramine 25–50 mg IV
was given approximately 30 min before temsirolimus infu-
sion to prevent potential hypersensitivity reactions. Cycles
were every 21 days except for cycle 1, which was 28 days.
Cycle 1 consisted of a run-in period of 1 week with
temsirolimus given alone on day 1, allowing for PK evalu-
ation of temsirolimus. For cycle 1 only, temsirolimus was
given on days 1, 8, 15 and 22, while RO4929097 was given
starting at cycle 1 day 8, using the 3/4 schedule (i.e. 3-days
on/4-days off). From cycle 2 onwards, cycles were 21 days in
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duration with RO4929097 administered on days 1–3, 8–10,
and 15–17 with weekly doses of IV temsirolimus on days 1,
8 and 15. Three dose levels were planned. Due to the ob-
served auto-induction of RO4929097 metabolism at doses
above 20 mg in the monotherapy trial [15], dose escalation of
R04929097 above 20 mg was not planned. DL3 included
37.5 mg temsirolimus in order to achieve blood levels equiv-
alent to the standard 25 mg weekly dose in the event of a
potential drug-drug interaction with RO49092907 mediated
by CYP3A4.
Toxicity was graded according to the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse
Events version (NCI CTCAE v4.0). Dose-limiting toxicities
(DLTs) were defined as adverse events (AEs) as least possi-
bly related to study medication(s) and fulfilling one of the
following criteria: a) grade 3 or 4 neutropenia complicated
by fever ≥38.5 °C, or grade 4 neutropenia of at least 7 days
duration; b) grade 3 thrombocytopenia complicated by hem-
orrhage or grade 4 thrombocytopenia; or c) any grade 3 or
higher non-hematologic toxicity (except anorexia, nausea,
vomiting, and diarrhea that was not optimally controlled
with appropriate medical intervention); d) any ≥grade 3
electrolyte abnormality including hypophosphatemia, hypo-
calcemia, or hypomagnesemia that did not resolve within
72 h with appropriate therapy or if it was associated with new
ECG changes; e) treatment-related toxicities that resulted in
failure to receive at least 75 % of the planned doses of
RO4929097 and of temsirolimus despite maximal support-
ive care measures; f) inability to resume dosing for cycle 2 at
the current dose level within 14 days due to treatment-related
toxicity.
A standard 3+3 design was used. Dose cohorts initially
included 3 patients. If 1 patient out of 3 experienced a DLT, 3
additional patients were treated at that dose level. If only 1
out of 6 patients in that dose level experienced a DLT,
escalation to the next level occurred. If 2 out of 3 or 2 out
of 6 patients experienced DLT, no further dose escalation
occurred. The Recommended Phase II Dose (RP2D) (equiv-
alent to Maximum Tolerated Dose (MTD)) was defined as
the dose level at which ≤1/6 patients experienced DLT. No
intra-patient escalation was allowed. Patients could continue
on study treatment until progressive disease was document-
ed. Low dose, non-myelosuppressive radiotherapy for symp-
tomatic palliation was permitted.
Patients who did not complete cycle 1 due to reasons
besides DLT (e.g. early withdrawal of consent, intercurrent
illness unrelated to study drugs, or symptomatic disease
progression) were replaced and were not considered
evaluable for DLT.
Patient evaluation
Pre-treatment evaluations were performed within 2 weeks of
treatment initiation and included history and physical exam-
ination, ECOG PS, hematology, serum chemistry, urinalysis,
and electrocardiogram (ECG). Physical examinations, hema-
tology and chemistry were repeated weekly during the first
cycle; and on day 1 of each subsequent cycle from cycle
2 onwards. Baseline radiological investigations were
performed within 28 days of treatment initiation. Objective
tumor response was assessed by Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 every two
cycles [5].
Dose modifications
Patients were required to meet the following criteria to re-
ceive study drugs on day 1 of each treatment cycle: absolute
neutrophil count ≥1.5×109, platelets ≥75×109, normal se-
rum electrolytes, non-hematologic toxicity recovered to
grade ≤1, and no evidence of disease progression.
Day 29=
Day 1 of cycle 2
Day 22=











Fig. 1 Treatment schedule.
Cycle 1 was 28-day long. Cycle
1, day 1 started with single-agent
temsirolimus administration,
allowing for pharmacokinetic
sampling, RO4929097 was first
administered at day 8. From
cycle 2 onwards, cycle duration
was 21 days. Temsirolimus was
administered weekly and
RO4929097 was given on a
3-days on/4-days off schedule,
prior to temsirolimus
administration
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Patients were withdrawn from the study if they failed to
recover to grade ≤1 or tolerable grade 2 (or within 1 grade of
starting values for pre-existing laboratory abnormalities)
from a treatment-related toxicity within 14 days or if they
experienced an agent-related AE that required dose modifi-
cation despite the number of permitted dose reductions (Sup-
plementary Table 1). If one agent was discontinued due to
toxicity, patients could continue to receive the other agent if,
in the opinion of the treating physician, the patient was
benefitting from treatment.
Study treatment continued until disease progression, an
unacceptable AE, withdrawal of consent, or changes in the
patient’s condition rendering further treatment unacceptable.
Pharmacokinetic (PK) analysis
Blood samples for RO4929097 and temsirolimus were col-
lected serially for PK analysis during cycle 1 and 2 (Supple-
mentary Tables 2 and 3). The unbound RO4929097
fractionswere obtained by filtrating plasma samples using
AmicoCentrifree® Micropartition devices (Millipore Corp.,
Bedford, MA, USA). Plasma temsirolimus, total and un-
bound RO4929097 concentrations were determined using
validated HPLC-tandem mass spectrometry methods [9,
17]. Pharmacokinetic parameters were calculated by non-
parametric methods using WinNonlin (Version 5.3,
Pharsight Corp., Sunnyvale, CA).
Notch pathway biomarkers
Archival paraffin-embedded tumorspecimens wererequested
on all subjects for immunohistochemical analysis of compo-
nents of the Notch pathway: Jagged-1, (NICD) and Notch-3.
Immunohistochemistry was performed using standard tech-
niques. Briefly, 4 μm paraffin-embedded tumor sections were
preheated to 57° for 15 min, cooled to room temperature,
dewaxed in xylene and rehydrated in graded alcohols. Endog-
enous peroxidase activity was blocked in 0.3 % hydrogen
peroxide in PBS for 30 min. Heat induced epitope retrieval
was accomplished using 10 mM citrate buffer (pH 6) in
Biocare Digital DecloakingChamber (using factory recom-
mended settings for IHC). Anti-NICD (Cell Signaling #2421;
1/50) and anti-Notch-3 (Santa Cruz Biotechnologies #sc-5593;
1/150) staining was performed using VECTASTAIN ABC Kit
(Rabbit IgG) (Vector Labs #PK-4001) with the following
modifications: permeablization with 0.3 % Triton X100 in
PBS for 2×10 min before block; block for 1 h room temper-
ature in PBS 3 % BSA, 20 mM MgCl2, 5 % FBS, 0.3 %
Tween20, plus Vector blocking sera); incubation with primary
antibody (diluted in blocking buffer plus vector blocking sera)
overnight at 4°; secondary antibody diluted 1/100 in PBS 5 %
BSA plus Vector blocking sera; all washes 2×5 min PBS,
followed by 2×5 min PBS 0.3 % Triton X100. Anti Jagged-
1 (R&D Systems #AF1277; 1/50) staining was performed
using Cell and Tissue Staining kit (Goat IgG) (R&D Systems
#CTS008) with a 4° overnight incubation with primary anti-
body. All immunohistochemistry was performed using Shan
don Sequenza immunostaining coverplates (Fisher #7219950)
and Peroxidase Substrate Kit, DAB (Vector Labs #SK-
4100). Slides were counterstained with hematoxylin,
dehydrated in graded alcohols to xylene, and mounted using
Permount.
The stained slides were scored centrally (the pathologist,
B.A.C., was blinded to the clinical outcome) for the presence
of Jagged-1, NICD, and Notch-3. The positive antibody reac-
tion was scored into four grades, according to the intensity of
the staining: 0, 1+, 2+ and 3+. The percentage of positive cells
was also scored into four categories: 0 (0 %), 1 (1–33 %), 2
(34–66 %), and 3 (67–100 %). The product of the intensity
and the percentage scores was used as the final score [1, 3].
Mutational analysis
In patients with available archival paraffin-embedded tumor
specimens and sufficient DNA, genotyping was performed
with either Sequenom MassARRAY (Sequenom) PMH v1.0
customized panel for solid tumors that includes 280 muta-
tions in 23 genes or the MiSeq (Illumina) TruSeq Amplicon
Cancer Panel (TSACP) panel that includes 212 amplicons in
48 genes in the CLIA-certified University Health Network
Advanced Molecular Diagnostics Laboratory.
Statistical analysis
Standard descriptive statistics, such as themean, median, range
and proportion, were used to summarize the patient sample and
frequency of AEs. Wilcoxon test was performed for compar-
ison of Notch biomarker protein expression between patient
subgroups. A fixed-effect ANOVA test was used to compare
temsirolimus PK parameters at three different time points
during cycle 1 (day 1, day 8 and day 15). Time to progression
(TTP) was defined as the time from start of treatment until
disease progression. Radiologic assessment of disease status
was repeated every 6 weeks. Univariate Cox proportional
hazard analysis was performed to assess the association be-
tween protein expression and TTP. Exact 95 % confidence
intervals were calculated for each proportion of interest. Sta-
tistical analysis was performed using SAS 9.2 software.
Results
Patient demographics
Between August 2010 and March 2012, 17 patients were
enrolled (7 males; 10 females). Median age was 62 (range
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28–84); most patients were ECOG PS 1 and had been treated
with a median of 3 lines of chemotherapy (Table 1). Most
common tumor types were sarcoma (n=6, 35 %), neuroen-
docrine (n=2, 12 %) and squamous cell carcinoma of the
head and neck (n=2, 12 %).
Dose escalation and RP2D
Eight, three, and six patients were enrolled in dose levels
(DL) 1, 2, and 3, respectively. Treatment is summarized in
Table 2. Two patients in DL1 (RO4929097 10 mg,
Temsirolimus 25 mg) were non-evaluable for DLT. One
patient voluntarily withdrew consent at day 22. Another
non-compliant patient in the first cohort did not receive two
of the four planned doses of temsirolimus. The two missed
doses could not be attributed to toxicity. Thus, this patient
was considered not evaluable for DLT. One patient in DL1
experienced two DLT events (grade 3 oral mucositis and
grade 3 maculo-papular rash), prompting treatment of three
additional patients at this dose level. No additional DLT
events were observed in the expanded DL1 allowing for
further dose escalation to DL2 (n=3). In DL2 and DL3, 0/3
patients initially treated experienced DLT. An additional 3
patients were treated at DL3 to better evaluate safety of this
dose level. No DLTs were observed (0/6 patients treated in
DL3), leading to a declaration of 20 mg of oral RO4929097
in a 3-days-on/4-days-off schedule along with 37.5 mg of
temsirolimus as the RP2D.
Safety and compliance
All 17 treated patients were evaluable for toxicity. The most
frequently reported treatment-related AEs are listed in
Table 3.
Fatigue (82 %) and oral mucositis (71 %) were the most
frequently reported non-hematological treatment-related AEs.
These were grade 1 and 2 in most cases and were easily
managed with standard supportive measures. Only one epi-
sode of grade 3 mucositis was observed. Maculo-papular rash
was observed in 7 patients (41 %), with only one grade 3
episode. Three patients (2 patients with grade 2; 1 patient with
grade 3) required treatment interruption due to rash. Rash was
reversible in all cases and no dose modification was needed
when treatment was resumed. Gastrointestinal toxicities, in-
cluding anorexia (47 %), nausea (41 %), vomiting (29 %), and
diarrhea (18 %) were also frequently observed. Consistent
with the single agent safety profile of RO4929097 and
temsirolimus, hypophosphatemia was frequently observed
(47 %). However, most episodes were grade 2, and were
managed with oral and/or intravenous supplementation. Pro-
longation of the QTc interval has been reported with
RO4929097. In this study, three patients (17 %) experienced
grade 1 asymptomatic transient QT interval prolongation. This
was not associated with electrolyte abnormalities. No clinical-
ly significant rhythm abnormalities were noted.
Metabolic disturbances and pneumonitis have been fre-
quently described with temsirolimus [12]. In this study,
hypertriglyceridemia was the most commonly reported
(n=10, 59 %) metabolic AE. Most cases were grade 1 and
2 in severity, and no intervention was required. A few in-
stances of hyperglycemia (n=4, 23 %) and hypercholester-
olemia (n=2, 12 %) were noted. Hyperglycemia was of
grade 1 or 2 severity in all cases, and was managed with diet
and/or oral antidiabetic medication. One patient with prior
history of hypercholesterolemia required statin treatment for
grade 3 hypercholesterolemia. Another patient received low-
Table 1 Patient demographics












Neuroendocrine tumor 2 (12)
SCCHN 2 (12)
Othera 7 (41)
No. prior chemotherapy regimens
Median 3
Range 1–8
SCCHN squamous cell carcinoma of the head and neck, GIST gastro-
intestinal stromal tumor
a Other tumors included ovarian, lung cancer(non-small cell carcino-
ma), gastrointestinal stromal tumor, melanoma, hepatocellular carcino-
ma, endometrial cancer, cholangiocarcinoma












1† 10 25 8 1 G3 rash, G3
mucositis
2 20 25 3 0
3^ 20 37.5 6 0
† 2 pts were not evaluable for DLT
^DL3 (RP2D) was expanded to 6 pts
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dose rosuvastatin for grade 2 hypercholesterolemia while on
treatment and maintained an adequate control throughout the
study duration. No dose modifications or study treatment
interruption was required for any metabolic abnormalities.
No episodes of pneumonitis were observed in this study.
Neutropenia (59 %) and anemia (59 %) were the most
common hematological toxicities. There were two grade 3
episodes of neutropenia that were not associated with infec-
tion. No patient discontinued study treatment due to hema-
tological toxicity.
Dose delays and dose modifications for RO4929097 and
temsirolimus are provided in Supplementary Table 4.
Antitumor activity
No objective responses were observed. Eleven patients
(73 %) had stable disease as their best response and six
patients (40 %) completed at least six cycles of treatment
(4 months) without experiencing disease progression. The
median progression-free survival was 4.2 months (95 %
confidence interval [CI], 1.5–8.7 months). Two patients,
diagnosed with a metastatic high-grade synovial sarcoma
and a metastatic gastrointestinal stromal tumor respectively,
who had disease progression to their last regimen, remain on
study treatment at cycle 13 and 17 at the time of data cutoff
(Nov 5, 2012).
Pharmacokinetics
Plasma exposure of RO4929097 was measured at day 8 and
day 22 (Fig. 2). A dose-proportional increase in RO4929097
exposure was not observed. Temsirolimus clearance was
significantly increased from cycle 1 day 1 to cycle 1 day
15 across all doses levels (p<0.01), but not between cycle
1 days 1 and 8 (Fig. 3a). Correspondingly, there was a
significant reduction in temsirolimus area under the curve
(AUC) from cycle 1 day 1 to cycle 1 day 15 (p<0.01),but not
between cycle 1 days 1 and 8 (Fig. 3b). No difference in peak
temsirolimus plasma concentrations (Cmax) was observed
among different dosing days in cycle 1. These findings are
Table 3 Treatment-related adverse events and laboratory abnormalitiesoccurring in ≥10 % of patients
Dose level (DL) DL 1 DL 2 DL 3 All
RO4929097 10 mg 20 mg 20 mg
Temsirolimus 25 mg 25 mg 37.5 mg
No. of patients 8 3 6 17
Grades All grades Grades 3/4 All grades Grades 3/4 All grades Grades 3/4 All grades (%) Grades 3/4 (%)
Fatigue 6 1 3 0 5 0 14 (82) 1(6)
Mucositis 5 1 2 0 5 0 12 (71) 1(6)
Anorexia 3 1 1 0 4 0 8 (47) 1(6)
Rash 3 1 2 0 2 0 7 (41) 1(6)
Nausea 3 1 1 0 3 0 7 (41) 1(6)
Dysgeusia 1 0 2 0 4 0 7 (41) 0
Vomiting 2 0 1 0 2 0 5 (29) 0
Diarrhea 2 0 1 0 0 0 3 (18) 0
Flu-like symptoms 0 0 1 0 2 0 3 (18) 0
Headache 0 0 1 0 2 0 3 (18) 0
QTc prolongation 2 0 0 0 1 0 3 (18) 0
Hematology
Neutropenia 3 1 2 0 5 1 10 (59) 2 (12)
Anemia 5 0 0 0 5 0 10 (59) 0
Thrombocytopenia 2 0 2 0 4 0 8 (47) 0
Chemistry
Hypertriglyceridemia 5 1 2 0 3 0 10 (59) 1(6)
Hypophosphatemia 4 0 2 1 2 1 8 (47) 2 (12)
Elevated AST 5 0 0 0 0 0 5 (29) 0
Elevated ALT 4 0 0 0 0 0 4 (23) 0
Hyperglycemia 2 0 1 0 1 0 4 (23) 0
Hypercholesterolemia 2 0 0 0 0 0 2 (12) 0
Proteinuria 1 0 0 0 1 0 2 (12) 0
DL dose level, AST aspartate aminotransferase, ALT alanine aminotransferase
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consistent with a cumulative effect of repetitive RO4929097
dosing on CYP3A4 induction leading to increased
temsirolimus clearance and reduced AUC.
Notch pathway biomarkers
Archival pathology specimens were available from 14 pa-
tients. Immunohistochemical (IHC) expression of Notch re-
ceptor ligand Jagged-1, Notch-3 receptor, and Notch intra-
cellular domain (NCID) was performed on paraffin-
embedded tumor tissue. The median Jagged-1 IHC intensity
score was 6 (range 3–7). The median Notch-3 score was 2
(range 0–7), and the median NCID score was 5 (range 0–8).
No significant differences in the median protein expression
score were seen between patients who remained progression-
free after four cycles of treatment and those who progressed
prior to cycle 5. No significant association was detected
between protein expression of any of the Notch biomarkers
evaluated and time to progression (Supplementary Table 5).
Of 14 tumors with archived pathology specimens and suffi-
cient DNA available for further analysis, mutations were
identified in 5 patients (Supplementary Table 6). No corre-
lation between mutational status (mutation(s) vs no muta-
tion(s)) and TTP was found.
Discussion
This study evaluated the feasibility of the combination of
RO4929097, an oral γ-secretase inhibitor, and temsirolimus
in patients with advanced solid tumors. The RP2D of such
combination was determined to be 20 mg of RO4929097 in
3-days on/4-days off weekly schedule along with the weekly
administration of 37.5 mg of temsirolimus. The most com-
mon treatment-related toxicities of the combination were
fatigue and mucositis. Other toxicities commonly seen with
temsirolimus were not exacerbated by the addition of
RO4929097 [4, 12].
It has been observed that RO4929097 exposure decreases
after repeated oral administration due to reversible CYP3A4
auto-induction at doses as low as 24 mg in the 3-days on/4-
days off schedule [15]. Thus, it was decided to start
RO4929097 dosing at 10 mg, and RO4929097 dose was
only escalated to 20 mg. However, even at these relatively
low doses, RO4929097 appears to induce CYP3A4 activity,
resulting in a significant increase in temsirolimus clearance
and a significant decrease in temsirolimus exposure.
No responses were seen with the combination of RO4929
097 and temsirolimus. Six evaluable patients (40%) received at
least six cycles of treatment, with SD as best response. Of note,
two patients, one with a gastrointestinal stromal tumor and the
other with a high-grade synovial sarcoma, remain on treatment
after more than 12 cycles.
This study has several limitations. Based on the previous-
ly observed auto- induction phenomenon with doses of
RO4929097 above 24 mg, RO4929097 was given at low
doses (10 mg in DL1; 20 mg in DL2 and DL3). However,
human doses of R04929097≥6 mg achieved plasma concen-
trations that exceed efficacious exposure levels established
in animal models (exposures producing efficacy (AUC24h)
were approximately 1,100 ng h/mL after oral daily dosing
schedule of 10 mg/kg/day for 21 days in rats, equivalent to
9 mg/day in humans). In fact, the lowest dose level of
RO4929097 tested in this study (10 mg) produced serum
concentrations above the minimum effective concentration
required to inhibit gamma secretase in xenograft studies
(data not shown). Secretory diarrhea is a potential pharma-
codynamic marker of Notch inhibition due to the critical role
of Notch in proper cell differentiation of the rapidly self-
renewing crypt cells of the small intestine [7]. Inhibiting γ-
Fig. 2 Plasma exposure of
RO4929097 (area under the
curve [AUC]) at day 8 and day
22, at the different dose levels.
Horizontal bars represent
standard deviation. Dose
level 1: RO4929097, 10 mg;
temsirolimus 25 mg. Dose
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secretase shifts the balance of celltypes from nutrient-
absorbing cells tomucus-secreting cells leading to secretory
diarrhea. Diarrhea was infrequently observed in our study (3
patients, 18 %, all grade 1 episodes), suggesting that the
doses and schedule of RO4929097 tested may not have been
adequate to inhibit Notch. Other putative pharmacodynamic
markers, including circulating Aß-40 protein and VEGFR2
protein levels in plasma, changes in interleukin-6 plasma
levels [15], andexpression of Notch pathway transcripts in
hair follicles, have been evaluated in studies of γ-secretase
inhibitors, although it is not clear if these biomarkers reflect
intratumoral Notch inhibition [15]. However, this study did
not include such pharmacodynamic assessments. Future
studies may require pre- and post-treatment paired tumor
biopsies in order to assess target engagement and the phar-
macodynamic effects of combined pathway inhibition.
Exploratory analysis of selected components of the Notch
signaling pathway (Jagged-1, NICD, and Notch-3 receptor)
a
b















Fig. 3 a Temsirolimus clearance
(Cl) observed at cycle day 1, day
8 and day 15 for the different
dose levels. Horizontal bars
represent standard deviation.
Dose level 1: RO4929097,
10 mg; temsirolimus 25 mg.
Dose level 2: RO4929097,
20 mg; temsirolimus 25 mg.
RO4929097, 20 mg;
temsirolimus 37.5 mg. (*)
denotes p value for comparison
between cycle 1 day 1 and cycle
1 day 8; (**) denotes p value for
comparison between cycle 1 day
1 and cycle 1 day 15. b
Temsirolimus area under the
curve (AUC) observed at cycle 1,
day1, day 8 and day 15 for the
different dose levels. Horizontal
bars represent standard
deviation. Dose level 1:
RO4929097, 10 mg;
temsirolimus 25 mg. Dose level
2: RO4929097, 20 mg;
temsirolimus 25 mg.
RO4929097, 20 mg;
temsirolimus 37.5 mg. (*)
denotes p value for comparison
between cycle 1 day 1 and cycle
1 day 8; (**) denotes p value for
comparison between cycle 1 day
1 and cycle 1 day 15
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evaluated by immunohistochemistry was performed using
paraffin embedded archival tumor specimens. There was no
association between protein expression of any of the Notch
components and progression free survival beyond 4 cycles,
although the number of patients included in this analysis was
limited. Most patients had been previously treated with sev-
eral chemotherapy regimens prior to starting on study treat-
ment. It is unknown whether exposure to prior cytotoxic
treatment affects the expression of different Notch pathway
components. Future studies should investigate whether ex-
pression of Notch pathway components in tumor biopsies
acquired before starting treatment is associated with clinical
outcome with Notch inhibitor therapy. Our study performed
targeted genotyping of tumors with sufficient DNA for anal-
ysis. We did not find an association between the mutational
status and clinical outcome. This may be due to small num-
bers and the mixed tumor types of the patients tested.
Notch signaling is an area of intense research for the devel-
opment of new anticancer therapies. Beyond γ-secretase inhib-
itors, other approaches currently being investigated include ther-
apeutic antibody targeting of individual notch receptors and their
Dll4 ligand [6, 14, 18]. The available clinical data from studies of
γ-secretase inhibitors suggest limited activity in advanced solid
tumors as monotherapy. The future of Notch pathway inhibition
may be in combination with cytotoxic and other targeted thera-
pies. Our study demonstrates that RO4929097 and temsirolimus
can be safely combined. Our trial was prematurely discontinued
before planned expansion cohorts at the RP2D in endometrial
and renal cell cancers could be evaluated because the clinical
development of RO4929097 was stopped due to its unfavorable
pharmacological profile. Future studies are warranted to evaluate
if combined Notch and PI3K/mTOR inhibition is an active anti-
cancer approach.
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